Abilita Bio Secures $7.5M in Financing
- Abilita Bio, a San Diego, CA-based leader in discovering and developing membrane protein-targeted therapeutics, raised $7.5M in equity financing
- Two Bear Capital made the investment. Mike Goguen, Managing Partner at Two Bear Capital, has joined Abilita Bio’s board
- The company intends to use the funds to accelerate existing preclinical therapeutic programs, initiate efforts on additional targets, grow the team, and expand operations in San Diego
- AbilitaBio is an innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically important multi-span membrane proteins
- Its validated drug discovery engine builds on the foundation of its EMP™ target evolution platform and deep membrane protein expertise to a suite of internal antibody discovery technologies
